These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38494058)

  • 1. CD32 (FcγRIIB) expression is low on CD21
    Kourkouni E; Tsiogkas SG; Mavropoulos A; Simopoulou T; Katsiari CG; Bogdanos DP; Sakkas LI
    Clin Immunol; 2024 May; 262():110195. PubMed ID: 38494058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD19 + CD21
    Wilfong EM; Vowell KN; Bunn KE; Rizzi E; Annapureddy N; Dudenhofer RB; Barnado A; Bonami RH; Johnson JE; Crofford LJ; Kendall PL
    Clin Exp Med; 2022 May; 22(2):209-220. PubMed ID: 34374937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.
    Fava A; Cimbro R; Wigley FM; Liu QR; Rosen A; Boin F
    Arthritis Res Ther; 2016 May; 18(1):99. PubMed ID: 27145754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis.
    Wortel CM; Liem SI; van Leeuwen NM; Boonstra M; Fehres CM; Stöger L; Huizinga TW; Toes RE; De Vries-Bouwstra J; Scherer HU
    RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
    Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial lung disease in systemic sclerosis.
    Bussone G; Mouthon L
    Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
    Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
    Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as potential makers for digital ulcers and interstitial lung disease in patients with systemic sclerosis: cross-sectional analysis of data from a prospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Sohn DH; Lee SG
    Rheumatol Int; 2020 Jul; 40(7):1071-1079. PubMed ID: 32424613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD21
    Visentini M; Pellicano C; Leodori G; Marrapodi R; Colantuono S; Gigante A; Casato M; Rosato E
    Clin Exp Immunol; 2021 Aug; 205(2):128-134. PubMed ID: 33876421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stem cells suppressed skin and lung inflammation and fibrosis in topoisomerase I-induced systemic sclerosis associated with lung disease mouse model.
    Ganesan N; Chang YD; Hung SC; Lan JL; Liao JW; Fu ST; Lee CC
    Cell Tissue Res; 2023 Feb; 391(2):323-337. PubMed ID: 36447073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.
    Kim D; Peck A; Santer D; Patole P; Schwartz SM; Molitor JA; Arnett FC; Elkon KB
    Arthritis Rheum; 2008 Jul; 58(7):2163-73. PubMed ID: 18576347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.
    Boonstra M; Bakker JA; Grummels A; Ninaber MK; Ajmone Marsan N; Wortel CM; Huizinga TWJ; Jordan S; Hoffman-Vold AM; Distler O; Toes REM; Scherer HU; de Vries-Bouwstra JK
    Arthritis Rheumatol; 2020 Nov; 72(11):1897-1904. PubMed ID: 32840062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus.
    Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Takahashi T; Toyama T; Ichimura Y; Noda S; Akamata K; Miyazaki M; Kuwano Y; Yanaba K; Sato S
    J Dermatol; 2014 May; 41(5):418-20. PubMed ID: 24801917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis.
    Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Iso S; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
    PLoS One; 2016; 11(8):e0161908. PubMed ID: 27564852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.
    Cavazzana I; Vojinovic T; Airo' P; Fredi M; Ceribelli A; Pedretti E; Lazzaroni MG; Garrafa E; Franceschini F
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):412-430. PubMed ID: 35716254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
    Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
    Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEACAM 1, 3, 5 and 6 -positive classical monocytes correlate with interstitial lung disease in early systemic sclerosis.
    Yokoyama K; Mitoma H; Kawano S; Yamauchi Y; Wang Q; Ayano M; Kimoto Y; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H
    Front Immunol; 2022; 13():1016914. PubMed ID: 36341379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement.
    Trombetta AC; Soldano S; Contini P; Tomatis V; Ruaro B; Paolino S; Brizzolara R; Montagna P; Sulli A; Pizzorni C; Smith V; Cutolo M
    Respir Res; 2018 Sep; 19(1):186. PubMed ID: 30249259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.